Encapsulated cannabinoid formulations for transdermal delivery
Preparation of cannabinoid formulations containing: Δ9-tetrahydrocannabinol (Δ9-THC), Δ8-tetrahydrocannabinol (Δ8-THC), Δ9-tetrahydrocannabinolic acid (THCa), cannabidiol (CBD), cannabidiolic acid (CBDa), cannabigerol (CBG), cannabichromene (CBC) and cannabinol (CBN), either alone or in combinations henceforth known as cannabis , have been created using an emulsification process to encapsulate cannabinoids. The aqueous-based method involves micellular encapsulation of cannabinoids, a method that has been used to increase the bioavailability of poorly permeable, lipophilic drugs. The present invention demonstrates the viability of transdermal delivery with gels and patches for consistent and sustained cannabinoid dosing.
1. A cannabinoid composition capable of trans canal delivery, comprising:
a cannabinoid composition further comprising:
a cannabinoid preparation ranging from 0.1% to 20% (w/w);
at least one surfactant ranging from 5% to 50% (w/w);
at least one co-solvent ranging from 10% to 70% (w/w);
water ranging from 16% to 60% (w/w); and
wherein the cannabinoid composition is capable of topical application and wherein the cannabinoid preparation is encapsulated by surfactants to form micelles having uni-, bi-, or multi-lamellar structures.
2. The cannabinoid composition of claim 1 , wherein the at least one surfactant comprises two surfactants.
3. The cannabinoid composition of claim 2 , wherein the two surfactants comprise air HLB in the range of 1 to 8 and form a self-assembling emulsion.
4. The cannabinoid composition of claim 1 , wherein the at least one surfactant comprises an HLB in the range of 9-20.
5. The cannabinoid composition of claim 1 , wherein the at least one surfactant is selected from a group consisting of: oleic acid, lecithin, phosphatidylcholine, isopropyl myristate, stearic acid, medium and long chain triglycerides (including Labrasol), polysorbate 20, polysorbate 80, or other ethoxylated surfactant, and sorbitan trioleate, or other sorbitan surfactant.
6. The cannabinoid composition of claim 1 , wherein the at least one co-solvent is selected from a group consisting of methanol, ethanol, isopropyl alcohol, butanol, pentanol, hexanol, ethylene glycol, propylene glycol, dipropylene glycol, glycerol, erythritol, mannitol, sorbitol, diethylene glycol monoethyl ether (Transcutol), any derivative thereof, and combinations relating thereto.
7. The cannabinoid composition of claim 1 , further comprising a thickening agent in the range of 0.01% to 5% (w/w).
8. The cannabinoid composition of claim 1 , further comprising terpenes in the range of 0.1% to 5% (w/w).
9. The cannabinoid composition of claim 1 , further comprising a preservative ranging from 0.01% to 2.5% (w/w).
10. The cannabinoid composition of claim 1 , further comprising a pH modifying agent to neutralize the composition.
11. The cannabinoid composition of claim 1 , wherein the cannabinoid composition is incorporated into a patch comprised of a reservoir and a backing film having an adhesive;
wherein the patch reservoir is capable of operably containing the cannabinoid composition within the backing film, and is capable of operably affixing to skin via the adhesive for transdermal delivery of the cannabinoid composition.
12. The cannabinoid composition of claim 11 , further comprising a rate-controlling membrane.
13. The cannabinoid composition of claim 11 , further comprising a drug encased reservoir.
14. The cannabinoid composition of claim 1 , wherein the cannabinoid composition for topical application in the form of an ointment, a cream, an emulsion, a lotion, a paste, an unguent, a gel or a sunscreen comprising therapeutically effective amounts of the cannabinoid composition.